585 related articles for article (PubMed ID: 29618309)
21. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.
Connock M; Juarez-Garcia A; Frew E; Mans A; Dretzke J; Fry-Smith A; Moore D
Health Technol Assess; 2006 Jun; 10(20):iii-iv, ix-113. PubMed ID: 16729919
[TBL] [Abstract][Full Text] [Related]
22. Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients.
Tanaka M; Ohashi T; Kobayashi M; Eto Y; Miyamura N; Nishida K; Araki E; Itoh K; Matsushita K; Hara M; Kuwahara K; Nakano T; Yasumoto N; Nonoguchi H; Tomita K
Clin Nephrol; 2005 Oct; 64(4):281-7. PubMed ID: 16240899
[TBL] [Abstract][Full Text] [Related]
23. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
[TBL] [Abstract][Full Text] [Related]
24. [Fabry's disease: new therapeutic options for this lysosomal storage disorder].
Grau AJ; Schwaninger M; Goebel HH; Beck M
Nervenarzt; 2003 Jun; 74(6):489-96. PubMed ID: 12799787
[TBL] [Abstract][Full Text] [Related]
25. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
[TBL] [Abstract][Full Text] [Related]
26. Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients.
Kugadas A; Artoni P; Ruangsiriluk W; Zhao M; Boukharov N; Islam R; Volfson D; Derakhchan K
PLoS One; 2024; 19(5):e0304415. PubMed ID: 38820517
[TBL] [Abstract][Full Text] [Related]
27. Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.
Morrissey RP; Philip KJ; Schwarz ER
Cardiovasc J Afr; 2011; 22(1):38-44. PubMed ID: 21298206
[TBL] [Abstract][Full Text] [Related]
28. Molecular genetic, biochemical, and clinical studies in three families with cardiac Fabry's disease.
Yoshitama T; Nakao S; Takenaka T; Teraguchi H; Sasaki T; Kodama C; Tanaka A; Kisanuki A; Tei C
Am J Cardiol; 2001 Jan; 87(1):71-5. PubMed ID: 11137837
[TBL] [Abstract][Full Text] [Related]
29. [Fabry's disease; towards a treatment].
Linthorst GE; Hollak CE; Bosman DK; Heymans HS; Aerts JM
Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2391-5. PubMed ID: 11145093
[TBL] [Abstract][Full Text] [Related]
30. Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene.
Garzuly F; Maródi L; Erdös M; Grubits J; Varga Z; Gelpi E; Rohonyi B; Mázló M; Molnár A; Budka H
Brain; 2005 Sep; 128(Pt 9):2078-83. PubMed ID: 15947062
[TBL] [Abstract][Full Text] [Related]
31. A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy.
Sheppard MN; Cane P; Florio R; Kavantzas N; Close L; Shah J; Lee P; Elliott P
Cardiovasc Pathol; 2010; 19(5):293-301. PubMed ID: 19631563
[TBL] [Abstract][Full Text] [Related]
32. Enzyme replacement therapy in patients with Fabry's disease.
Tsuboi K
J Int Med Res; 2007; 35(4):574-81. PubMed ID: 17697536
[TBL] [Abstract][Full Text] [Related]
33. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].
Fabrega S; Lehn P
J Soc Biol; 2002; 196(2):175-81. PubMed ID: 12360746
[TBL] [Abstract][Full Text] [Related]
34. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.
Spinelli L; Pisani A; Sabbatini M; Petretta M; Andreucci MV; Procaccini D; Lo Surdo N; Federico S; Cianciaruso B
Clin Genet; 2004 Aug; 66(2):158-65. PubMed ID: 15253767
[TBL] [Abstract][Full Text] [Related]
35. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
36. [Ocular findings in Fabry's disease].
Kuzman T; Juri J; Mrsić M; Jeren-Strujić B; Mandić Z; Sikić J
Acta Med Croatica; 2006; 60(2):163-6. PubMed ID: 16848212
[TBL] [Abstract][Full Text] [Related]
37. Renal histology before and after effective enzyme replacement therapy in a patient with classical Fabry's disease.
Hirashio S; Taguchi T; Naito T; Maki K; Ogata S; Taniyama K; Taniguchi Y; Yorioka N
Clin Nephrol; 2009 May; 71(5):550-6. PubMed ID: 19473616
[TBL] [Abstract][Full Text] [Related]
38. Fabry's disease.
Zarate YA; Hopkin RJ
Lancet; 2008 Oct; 372(9647):1427-35. PubMed ID: 18940466
[TBL] [Abstract][Full Text] [Related]
39. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
[TBL] [Abstract][Full Text] [Related]
40. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women.
Gupta S; Ries M; Kotsopoulos S; Schiffmann R
Medicine (Baltimore); 2005 Sep; 84(5):261-268. PubMed ID: 16148726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
